Welcome to LookChem.com Sign In|Join Free

CAS

  • or
4,-carbamoyl-3-(naphthalen-1-ylmethoxy)-[1,1,-biphenyl]-4-carboxylic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1221890-31-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1221890-31-8 Structure
  • Basic information

    1. Product Name: 4,-carbamoyl-3-(naphthalen-1-ylmethoxy)-[1,1,-biphenyl]-4-carboxylic acid
    2. Synonyms:
    3. CAS NO:1221890-31-8
    4. Molecular Formula:
    5. Molecular Weight: 397.43
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1221890-31-8.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 4,-carbamoyl-3-(naphthalen-1-ylmethoxy)-[1,1,-biphenyl]-4-carboxylic acid(CAS DataBase Reference)
    10. NIST Chemistry Reference: 4,-carbamoyl-3-(naphthalen-1-ylmethoxy)-[1,1,-biphenyl]-4-carboxylic acid(1221890-31-8)
    11. EPA Substance Registry System: 4,-carbamoyl-3-(naphthalen-1-ylmethoxy)-[1,1,-biphenyl]-4-carboxylic acid(1221890-31-8)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1221890-31-8(Hazardous Substances Data)

1221890-31-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1221890-31-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,1,8,9 and 0 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1221890-31:
(9*1)+(8*2)+(7*2)+(6*1)+(5*8)+(4*9)+(3*0)+(2*3)+(1*1)=128
128 % 10 = 8
So 1221890-31-8 is a valid CAS Registry Number.

1221890-31-8Downstream Products

1221890-31-8Relevant articles and documents

Discovery of novel allosteric non-bisphosphonate inhibitors of farnesyl pyrophosphate synthase by integrated lead finding

Marzinzik, Andreas L.,Amstutz, René,Bold, Guido,Bourgier, Emmanuelle,Cotesta, Simona,Glickman, J. Fraser,G?tte, Marjo,Henry, Christelle,Lehmann, Sylvie,Hartwieg, J. Constanze D.,Ofner, Silvio,Pellé, Xavier,Roddy, Thomas P.,Rondeau, Jean-Michel,Stauffer, Frédéric,Stout, Steven J.,Widmer, Armin,Zimmermann, Johann,Zoller, Thomas,Jahnke, Wolfgang

, p. 1884 - 1891 (2015/11/10)

Farnesyl pyrophosphate synthase (FPPS) is an established target for the treatment of bone diseases, but also shows promise as an anticancer and anti-infective drug target. Currently available anti-FPPS drugs are active-site-directed bisphosphonate inhibitors, the peculiar pharmacological profile of which is inadequate for therapeutic indications beyond bone diseases. The recent discovery of an allosteric binding site has paved the way toward the development of novel non-bisphosphonate FPPS inhibitors with broader therapeutic potential, notably as immunomodulators in oncology. Herein we report the discovery, by an integrated lead finding approach, of two new chemical classes of allosteric FPPS inhibitors that belong to the salicylic acid and quinoline chemotypes. We present their synthesis, biochemical and cellular activities, structure-activity relationships, and provide X-ray structures of several representative FPPS complexes. These novel allosteric FPPS inhibitors are devoid of any affinity for bone mineral and could serve as leads to evaluate their potential in none-bone diseases. Beyond the bone: Farnesyl pyrophosphate synthase (FPPS) is an important target for osteoporosis and bone metastases, and holds promise for a number of non-bone diseases, including cancer, parasitic infections, progeria, and Alzheimer's disease. Herein we describe two novel chemotypes of allosteric FPPS inhibitors. These are useful leads to evaluate the therapeutic potential of FPPS inhibitors for these new indications.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1221890-31-8